3062 Ceritinib following crizotinib in ALK-positive (+) advanced NSCLC patients (pts): Results from the French Temporary Authorization for Use (ATU) experience

Saved in:
Bibliographic Details
Published inEuropean journal of cancer (1990) Vol. 51; pp. S616 - S617
Main Authors Cadranel, J., Cortot, A., Lena, H., Mennecier, B., Do, P., Dansin, E., Mazieres, J., Chouaid, C., Perol, M., Barlesi, F.
Format Journal Article
LanguageEnglish
Published Elsevier Ltd 01.09.2015
Subjects
Online AccessGet full text
ISSN0959-8049
1879-0852
DOI10.1016/S0959-8049(16)31704-X

Cover

Author Mazieres, J.
Chouaid, C.
Cadranel, J.
Do, P.
Lena, H.
Mennecier, B.
Dansin, E.
Cortot, A.
Perol, M.
Barlesi, F.
Author_xml – sequence: 1
  givenname: J.
  surname: Cadranel
  fullname: Cadranel, J.
– sequence: 2
  givenname: A.
  surname: Cortot
  fullname: Cortot, A.
– sequence: 3
  givenname: H.
  surname: Lena
  fullname: Lena, H.
– sequence: 4
  givenname: B.
  surname: Mennecier
  fullname: Mennecier, B.
– sequence: 5
  givenname: P.
  surname: Do
  fullname: Do, P.
– sequence: 6
  givenname: E.
  surname: Dansin
  fullname: Dansin, E.
– sequence: 7
  givenname: J.
  surname: Mazieres
  fullname: Mazieres, J.
– sequence: 8
  givenname: C.
  surname: Chouaid
  fullname: Chouaid, C.
– sequence: 9
  givenname: M.
  surname: Perol
  fullname: Perol, M.
– sequence: 10
  givenname: F.
  surname: Barlesi
  fullname: Barlesi, F.
BookMark eNqNkNtqGzEURUVJoE7STyjo0aZMIo3mpkIbzJAbMS00DvhNyJqjWslYGqSxc_mZ_Gpku-ShENonccTZS1vrAO1ZZwGhz5QcU0KLkxvCc55UJONDWowYLUmWzD6gAa1KnpAqT_fQ4G3lIzoI4Y4QUlYZGaAXRooU1-BNb6yZY-3a1j0Y-xsrb57d7tJYPJ5cJ50LcWsNePhlhGWzllZBg3_c1JMad7I3YPuAh10fRl_xLwirNo7auyXuF4DPPVi1wFNYds5L_4THq37h4hsx6Gx81-PbENHj6e0Iw2MXG8UAHKF9LdsAn_6ch2h6fjatL5PJz4urejxJVErpLNHNXKuCMZ3LLIWGFVrSpmRKZXOmoiRQUEpOqM4kYSqdc17wPKU8yypCJWOHKN9hlXcheNCi82YZawpKxEay2EoWG4MiTlvJYhZzp7scxG5rA14Ete3dGA-qF40z_yR8_4ug2ihdyfYeniDcuZW38eOCipAKsoNsGLTYEjaAb-8D_qPAK40Ir0k
ContentType Journal Article
Copyright 2015 European Cancer Congress
European Cancer Congress
Copyright_xml – notice: 2015 European Cancer Congress
– notice: European Cancer Congress
DBID AAYXX
CITATION
DOI 10.1016/S0959-8049(16)31704-X
DatabaseName CrossRef
DatabaseTitle CrossRef
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1879-0852
EndPage S617
ExternalDocumentID 10_1016_S0959_8049_16_31704_X
S095980491631704X
1_s2_0_S095980491631704X
GroupedDBID ---
--K
--M
.1-
.55
.FO
.GJ
.~1
0R~
1B1
1P~
1RT
1~.
1~5
29G
3O-
4.4
457
4G.
53G
5GY
5RE
5VS
6PF
7-5
71M
8P~
9JM
AABNK
AAEDT
AAEDW
AAIKJ
AAKOC
AALRI
AAOAW
AAQFI
AAQXK
AATTM
AAWTL
AAXKI
AAXUO
AAYWO
ABBQC
ABFNM
ABGSF
ABJNI
ABLJU
ABMAC
ABMZM
ABOCM
ABUDA
ABWVN
ABXDB
ACDAQ
ACIEU
ACIUM
ACPRK
ACRLP
ACRPL
ACVFH
ADBBV
ADCNI
ADEZE
ADMUD
ADNMO
ADUVX
AEBSH
AEHWI
AEIPS
AEKER
AENEX
AEUPX
AEVXI
AFFNX
AFJKZ
AFPUW
AFRAH
AFRHN
AFTJW
AFXIZ
AGCQF
AGHFR
AGQPQ
AGRDE
AGUBO
AGYEJ
AHHHB
AIEXJ
AIGII
AIIUN
AIKHN
AITUG
AJRQY
AJUYK
AKBMS
AKRWK
AKYEP
ALMA_UNASSIGNED_HOLDINGS
AMRAJ
ANKPU
ANZVX
APXCP
ASPBG
AVWKF
AXJTR
AZFZN
BKOJK
BLXMC
BNPGV
CS3
DU5
EBS
EFJIC
EFKBS
EJD
EO8
EO9
EP2
EP3
F5P
FDB
FEDTE
FGOYB
FIRID
FNPLU
FYGXN
G-2
G-Q
GBLVA
HED
HMK
HMO
HVGLF
HZ~
IHE
J1W
K-O
KOM
M29
M41
MO0
N9A
O-L
O9-
OAUVE
OC~
OO-
OZT
P-8
P-9
P2P
PC.
Q38
R2-
ROL
RPZ
SAE
SCC
SDF
SDG
SDP
SEL
SES
SEW
SPCBC
SSH
SSU
SSZ
T5K
UV1
WUQ
X7M
XPP
Z5R
ZGI
ZXP
~G-
AACTN
AFCTW
AFKWA
AJOXV
AMFUW
RIG
AAIAV
ABLVK
ABYKQ
AHPSJ
AJBFU
DOVZS
EFLBG
LCYCR
ZA5
AAYXX
AGRNS
CITATION
ID FETCH-LOGICAL-c211X-fdbfc633f5a42ed36fa1d73cc4b3c101ece7a901f4a03c2b9969521944801a33
IEDL.DBID AIKHN
ISSN 0959-8049
IngestDate Tue Jul 01 01:05:20 EDT 2025
Fri Feb 23 02:18:44 EST 2024
Sun Feb 23 10:18:55 EST 2025
Tue Aug 26 16:31:38 EDT 2025
IsPeerReviewed true
IsScholarly true
Language English
License https://www.elsevier.com/tdm/userlicense/1.0
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c211X-fdbfc633f5a42ed36fa1d73cc4b3c101ece7a901f4a03c2b9969521944801a33
ParticipantIDs crossref_primary_10_1016_S0959_8049_16_31704_X
elsevier_sciencedirect_doi_10_1016_S0959_8049_16_31704_X
elsevier_clinicalkeyesjournals_1_s2_0_S095980491631704X
elsevier_clinicalkey_doi_10_1016_S0959_8049_16_31704_X
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate September 2015
PublicationDateYYYYMMDD 2015-09-01
PublicationDate_xml – month: 09
  year: 2015
  text: September 2015
PublicationDecade 2010
PublicationTitle European journal of cancer (1990)
PublicationYear 2015
Publisher Elsevier Ltd
Publisher_xml – name: Elsevier Ltd
SSID ssj0007840
Score 2.1517534
SourceID crossref
elsevier
SourceType Index Database
Publisher
StartPage S616
SubjectTerms Hematology, Oncology and Palliative Medicine
Title 3062 Ceritinib following crizotinib in ALK-positive (+) advanced NSCLC patients (pts): Results from the French Temporary Authorization for Use (ATU) experience
URI https://www.clinicalkey.com/#!/content/1-s2.0-S095980491631704X
https://www.clinicalkey.es/playcontent/1-s2.0-S095980491631704X
https://dx.doi.org/10.1016/S0959-8049(16)31704-X
Volume 51
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3da9swED_aFMZexrZuLN1W7mEPCUNNZPkrewtmIVvbPLQJ-E1ItkwDxQlxukEf-q_0X-3JltONFQp71MFJRne-D-l-J4AvRsWkSCPFOBcZs-8hsVjnOQtGgZdHOtRDY7HD57NwuvB_pkG6B0mLhbFllc72Nza9ttaOMnC7OVgvl4NLe4IVU4BLEQWPhn66Dwceefu4AwfjH6fT2c4gR3GNi2xOvIjhEcjTTFITezzs1_Ow9GkX9YfbmbyGVy5exHHzSW9gz5Rv4cW5uxE_hHsKxj1MjO1NVC41FiTX1W_yR0jm4HbVEJcljs9OWVOg9ctg72sf28t_nF0mZwm6_qoV9tbbqv8NL0x1c01DCz9BChJxYmGBVzhvW1mhPVxbbRyMk9bd4KKiqcfzRR_NroHyO5hPvs-TKXOPLrCMcsGUFbkuslCIIlC-Z3IRFornkcgyX4uM9sxkJlIURBS-GorM05QvkVj5yLd9aJQQ76FTrkrzATAmime4KSgn8YlVF5EYKTKwXkRJYqy6cNJus1w3rTXkY80ZyUVauUga1XKRaRfCVhiyxY2SpZNk_J9jjJ5iNJX7XyvJZeXJofxHp7oQ7zj_UsvnFz36f9aP8JLisqApZfsEne3mxnym2Gerj2H_5I4fOw1_AKZ9_IM
linkProvider Elsevier
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwED-NTgJe0BigFRjcwx5aIdMmzld5qyKqbv142FIpb5adOFollFZNBxL_DP8q58TpQEyaxKNPOjvyXc4_2_c7A1xoGZEjjSRzHJ4x8x4Si1SeM3_ku3moAjXUhju8WAbTlXeV-ukRxC0XxqRV2tjfxPQ6WlvJwM7mYLteD27MCVZEAJcQhRMOvfQJHHvmUesOHI8vZ9PlISCHUc2LbE68SOGeyNN0Ugt7TtCv-2Hpw0vUH8vO5AReWLyI4-aTXsKRLk_h6cLeiL-CXwTGXYy1qU1UrhUWZNfND1qPkMLBz00jXJc4ns9Yk6D1XWPvUx_by39c3sTzGG191Qp7233V_4LXurr7Rk1DP0ECiTgxtMBbTNpSVmgO1zY7S-OkcXe4qqjrcbLqoz4UUH4NyeRrEk-ZfXSBZbQXTFmRqyILOC986bk650EhnTzkWeYpntGc6UyHkkBE4ckhz1xF-yUyqzPyTB0ayfkb6JSbUp8BRiRxtaML2pN4pKqKkI8kBVg3pE1iJLvwuZ1msW1Ka4j7nDOyizB2EdSq7SLSLgStMUTLG6VIJyj4P6YYPqSoK_u_VsIRlSuG4h-f6kJ00PzLLR8f9O3_q36EZ9NkMRfzy-XsHTwnjOY3aW3vobPf3elzwkF79cH6-W-ZAf5p
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=3062+Ceritinib+following+crizotinib+in+ALK-positive+%28%2B%29+advanced+NSCLC+patients+%28pts%29%3A+Results+from+the+French+Temporary+Authorization+for+Use+%28ATU%29+experience&rft.jtitle=European+journal+of+cancer+%281990%29&rft.au=Cadranel%2C+J.&rft.au=Cortot%2C+A.&rft.au=Lena%2C+H.&rft.au=Mennecier%2C+B.&rft.date=2015-09-01&rft.pub=Elsevier+Ltd&rft.issn=0959-8049&rft.eissn=1879-0852&rft.volume=51&rft.spage=S616&rft.epage=S617&rft_id=info:doi/10.1016%2FS0959-8049%2816%2931704-X&rft.externalDocID=S095980491631704X
thumbnail_m http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F09598049%2FS0959804915X00165%2Fcov150h.gif